MGC Pharmaceuticals undertook safety and toxicity pre-clinical studies using in vivo testing on mice in Israel and found that ArtemiC delivered "no adverse results in standard toxicity measures."
MGC Pharmaceuticals (ASX:MXC) is a Europe-based biotech company that is focused on the development of phytocannabinoid medicines to treat a range of diseases. Today, MGC announced that the company had completed a safety and toxicity study on its natural supplement formula known as 'ArtemiC,' which is comprised of Artemisinin, Curcumin and other supporting ingredients that share anti-infective, anti-inflammatory, immune-modulatory and antioxidant properties.
Performed in the Science in Action Laboratory in Ness Ziona, Israel, the pre-clinical trial which was conducted on mice revealed "no clinical signs or adverse reactions [to ArtemiC] from the full panel of hematology and chemistry blood tests."
According to the Press Release, 'The pre-clinical study was completed on nine mice in three study groups, with three mice per group. The mice in each group were given either 25ul, 50ul or none (the control group) and the mice were observed and tested for clinical changes over seven days. This study was conducted as a non-GLP (Good Laboratory Practice) study as GLP regulation for this type of study is not required or mandatory for product registration and the FDA does not require GLP for safety in vivo.'
The positive results from the safety trials affirm MGC's Phase II clinical trial on COVID-19 patients using ArtemiC. MGC's COVID-19 trial commenced in Israel at the Nazareth Hospital EMMS and Hillel Yaffe Hospital in May 2020, which the company says is "progressing on schedule."
The company expects initial results from the trial to be released in August, with the next phase of the ArtemiC study to include dosage analysis. Additionally, MGC states that "the significant spike in COVID-19 infection rates in Israel over the past 6 weeks has led to an increase in patient recruitment applications and the COVID19 infected patient pool."
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "We are very pleased with these results achieved in the ArtemiC safety and toxicity study. Importantly, this study provides further support for the parameters of our Phase II clinical trial in COVID-19 patients currently underway. We look forward to receiving the histology results from this in vivo study in the coming days, to be followed by the first interim results from our Phase II clinical trial in Israel on COVID-19 infected patients that are now expected by early August."
To find out more about MGC Pharmaceuticals, visit their HQ here.
Disclaimer: Past performance is not an indicator of future performance.
& Keep Up to Date
Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!